Moffat, John

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 1,134

Opportunities and challenges in phenotypic drug discovery: an industry perspective

Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery

Computational Drug Discovery MethodsAnimal testing and alternatives

Cited by 939

Phenotypic screening in cancer drug discovery — past, present and future

Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery

Computational Drug Discovery MethodsCancer Cells and Metastasis

Cited by 507

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences

Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 398

Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 60